May 23, 2019
5 min watch
Save

VIDEO: Novartis updates product pipeline

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

VANCOUVER, British Columbia — Dirk Sauer, PhD, Novartis global head of research and development, gives an update on the company’s portfolio, including Luxturna, brolucizumab and a possible presbyopia treatment, at the Association for Research in Vision and Ophthalmology meeting.